SMMT · CIK 1599298
What Summit Therapeutics Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for SMMT. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- China reliance via Akeso (sole-product license & manufacturing)high
Summit's lead (and effectively sole) product candidate ivonescimab is licensed from and manufactured by Akeso in China, making its operations and prospects heavily dependent on Chinese economic, political, and legal developments and the US-China trade relationship.
“As a result of our reliance on Akeso, located in China, our results of operations, financial condition, and prospects are subject to a significant degree to economic, political, and legal developments in China including government control over capital investments or changes in tax regulations that are applicable to us.”
Regulatory & policy
- DOJ bulk-data 'Countries of Concern' rule (China data transfer)medium
The DOJ rule restricting bulk data transactions involving Countries of Concern (incl. China and Hong Kong) could significantly impact Summit's clinical vendor engagements, collaborations, and partnerships — central to its Akeso relationship — if no lawful transfer mechanism or exemption applies.
“The Rule's restrictions could significantly impact some of our business activities, such as clinical related vendor engagements and collaborations and partnerships.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Akeso, Inc.
“We rely on the use of third parties, including Akeso, to manufacture our product candidate.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch